Lipocine (LPCN) Competitors $2.98 +0.04 (+1.36%) Closing price 09/12/2025 03:57 PM EasternExtended Trading$3.00 +0.02 (+0.50%) As of 09/12/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPCN vs. ABVC, IMMX, HOWL, BTAI, CLNN, CUE, DTIL, DRRX, COEP, and VTVTShould you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include ABVC BioPharma (ABVC), Immix Biopharma (IMMX), Werewolf Therapeutics (HOWL), BioXcel Therapeutics (BTAI), Clene (CLNN), Cue Biopharma (CUE), Precision BioSciences (DTIL), DURECT (DRRX), Coeptis Therapeutics (COEP), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry. Lipocine vs. Its Competitors ABVC BioPharma Immix Biopharma Werewolf Therapeutics BioXcel Therapeutics Clene Cue Biopharma Precision BioSciences DURECT Coeptis Therapeutics vTv Therapeutics Lipocine (NASDAQ:LPCN) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations. Do insiders & institutionals hold more shares of LPCN or ABVC? 9.1% of Lipocine shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 6.4% of Lipocine shares are owned by company insiders. Comparatively, 17.1% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is LPCN or ABVC more profitable? Lipocine has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. Lipocine's return on equity of -23.59% beat ABVC BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets LipocineN/A -23.59% -21.91% ABVC BioPharma -963.46%-46.76%-23.02% Do analysts prefer LPCN or ABVC? Lipocine presently has a consensus price target of $9.00, suggesting a potential upside of 202.01%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, LPCN or ABVC? Lipocine has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Which has better valuation & earnings, LPCN or ABVC? Lipocine has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipocine$11.20M1.44$10K-$0.87-3.43ABVC BioPharma$391.24K171.49-$4.90M-$0.17-16.76 Does the media refer more to LPCN or ABVC? In the previous week, ABVC BioPharma had 1 more articles in the media than Lipocine. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for Lipocine. ABVC BioPharma's average media sentiment score of 0.95 beat Lipocine's score of 0.88 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Lipocine Positive ABVC BioPharma Positive SummaryLipocine beats ABVC BioPharma on 11 of the 17 factors compared between the two stocks. Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPCN vs. The Competition Export to ExcelMetricLipocineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.93M$2.59B$5.86B$10.14BDividend YieldN/A56.51%5.68%4.59%P/E Ratio-3.4323.5374.5225.93Price / Sales1.44699.46547.62126.81Price / CashN/A171.1637.5660.44Price / Book0.765.3712.166.29Net Income$10K$32.95M$3.28B$270.77M7 Day Performance3.11%1.28%0.87%3.88%1 Month Performance-1.00%6.09%4.96%4.88%1 Year Performance-35.36%-2.15%60.75%26.01% Lipocine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPCNLipocine3.177 of 5 stars$2.98+1.4%$9.00+202.0%-27.0%$15.93M$11.20M-3.4310ABVCABVC BioPharma0.6982 of 5 stars$2.72+2.6%N/A+312.9%$62.39M$510K-16.0030IMMXImmix Biopharma2.953 of 5 stars$2.17+0.9%$7.00+222.6%+15.8%$61.99MN/A-2.829News CoverageAnalyst ForecastShort Interest ↑HOWLWerewolf Therapeutics3.9773 of 5 stars$1.33-1.5%$8.00+501.5%-33.8%$61.73M$1.88M-0.8140BTAIBioXcel Therapeutics4.0594 of 5 stars$4.23+11.6%$39.75+839.7%-64.7%$60.67M$2.27M-0.3390Short Interest ↑CLNNClene3.2088 of 5 stars$6.63+10.0%$33.00+397.7%-8.5%$60.24M$340K-1.76100News CoverageAnalyst ForecastHigh Trading VolumeCUECue Biopharma2.7157 of 5 stars$0.78-0.4%N/A+27.8%$59.94M$9.29M-1.3960DTILPrecision BioSciences4.184 of 5 stars$4.97-2.0%$47.00+845.7%-56.1%$59.76M$68.70M-0.56200News CoverageGap DownDRRXDURECT1.508 of 5 stars$1.96+2.6%N/AN/A$59.31M$1.66M-19.6080News CoverageOptions VolumeCOEPCoeptis Therapeutics0.9052 of 5 stars$12.95+5.5%N/A+244.0%$59.15MN/A-2.232Positive NewsVTVTvTv Therapeutics2.6131 of 5 stars$18.76+2.5%$35.50+89.2%+35.1%$58.49M$1.02M-6.019Gap UpHigh Trading Volume Related Companies and Tools Related Companies ABVC Alternatives IMMX Alternatives HOWL Alternatives BTAI Alternatives CLNN Alternatives CUE Alternatives DTIL Alternatives DRRX Alternatives COEP Alternatives VTVT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPCN) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LPCN Stock Alerts